Chemotherapy Protocol

LYMPHOMA

CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE

(RCVP)

Regimen

- Lymphoma – RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine

Indication

- Non-Hodgkin’s Lymphoma

Toxicity

<table>
<thead>
<tr>
<th>Drug</th>
<th>Adverse Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td>Dysuria, haemorrhagic cystitis (rare), taste disturbances</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>Weight gain, GI disturbances, hyperglycaemia, CNS disturbances, cushingoid changes, glucose intolerance</td>
</tr>
<tr>
<td>Rituxumab</td>
<td>Severe cytokine release syndrome, increased incidence of infective complications, progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>Vincristine</td>
<td>Peripheral neuropathy, constipation, jaw pain</td>
</tr>
</tbody>
</table>

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

Monitoring

Drugs

- FBC, LFTs and U&Es prior to day one of treatment
- Check hepatitis B status before starting treatment with rituximab

Dose Modifications

The dose modifications listed are for haematological, liver and renal function and drug specific toxicities only. Dose adjustments may be necessary for other toxicities as well.

In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped.

Please discuss all dose reductions / delays with the relevant consultant before prescribing, if appropriate. The approach may be different depending on the clinical circumstances.
Haematological

Dose modifications for haematological toxicity in the table below are for general guidance only. Always refer to the responsible consultant as any dose reductions or delays will be dependent on clinical circumstances and treatment intent. Low counts can be a consequence of bone marrow infiltration as well as drug toxicity.

Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL.

Dose modifications based on haematological parameters apply to cyclophosphamide alone.

<table>
<thead>
<tr>
<th>Neutrophils (x10⁹/L)</th>
<th>Dose Modifications (cyclophosphamide only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 or greater</td>
<td>100%</td>
</tr>
<tr>
<td>0.5 – 0.9</td>
<td>1st Occurrence</td>
</tr>
<tr>
<td></td>
<td>If no growth factor prophylaxis has been previously given then administer 100% of the doses with prophylactic growth factors</td>
</tr>
<tr>
<td></td>
<td>An alternative approach, where the individual has a poor performance status or the intent in not curative is to delay until the neutrophils are 1x10⁹/L and give 75% of the original dose as well as prophylactic growth factors</td>
</tr>
<tr>
<td></td>
<td>2nd Occurrence</td>
</tr>
<tr>
<td></td>
<td>Delay until neutrophils are 1x10⁹/L or above and then give 50% of the original dose as well as growth factors</td>
</tr>
<tr>
<td>Less than 0.5 or febrile neutropenia</td>
<td>1st Occurrence</td>
</tr>
<tr>
<td></td>
<td>Delay until the neutrophils are 1x10⁹/L or above and then give 75% of the original dose as well as prophylactic growth factors</td>
</tr>
<tr>
<td></td>
<td>2nd Occurrence</td>
</tr>
<tr>
<td></td>
<td>Delay until neutrophils are 1x10⁹/L or above and then give 50% of the original dose as well as growth factors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Platelets (x10⁹/L)</th>
<th>Dose Modifications (cyclophosphamide only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>75 or above</td>
<td>100%</td>
</tr>
<tr>
<td>50 – 74</td>
<td>1st Occurrence</td>
</tr>
<tr>
<td></td>
<td>Give 75% dose of the original dose</td>
</tr>
<tr>
<td></td>
<td>2nd Occurrence</td>
</tr>
<tr>
<td></td>
<td>Give 50% dose of the original dose</td>
</tr>
<tr>
<td>Less than 50 or signs of active haemorrhage</td>
<td>1st Occurrence</td>
</tr>
<tr>
<td></td>
<td>Delay until the platelets are 75 or above then give 75% of the original dose</td>
</tr>
<tr>
<td></td>
<td>2nd Occurrence</td>
</tr>
<tr>
<td></td>
<td>Delay until the platelets are 75 or above then give 50% of the original dose</td>
</tr>
</tbody>
</table>
Hepatic Impairment

Please note that the approach may be different where abnormal liver function tests are due to disease involvement.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Bilirubin (μmol/L)</th>
<th>AST/ALT (units/L)</th>
<th>Dose (% of original dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td></td>
<td></td>
<td>Evidence suggests no dose modification necessary.</td>
</tr>
<tr>
<td>Rituximab</td>
<td></td>
<td></td>
<td>No dose adjustment necessary.</td>
</tr>
<tr>
<td>Vincristine</td>
<td>*30-51 Or 60-180</td>
<td></td>
<td>50%</td>
</tr>
<tr>
<td></td>
<td>more than 51 and</td>
<td>normal</td>
<td>50%</td>
</tr>
<tr>
<td></td>
<td>more than 51 and</td>
<td>more than 180</td>
<td>omit</td>
</tr>
</tbody>
</table>

* Lower limit reflects local practice and may vary from published sources.

Renal Impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Creatinine Clearance (ml/min)</th>
<th>Dose (% of original dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide**</td>
<td>more than 20</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>10-20</td>
<td>75%</td>
</tr>
<tr>
<td></td>
<td>less than 10</td>
<td>50%</td>
</tr>
<tr>
<td>Rituximab</td>
<td>N/A</td>
<td>No dose adjustment needed</td>
</tr>
<tr>
<td>Vincristine</td>
<td>N/A</td>
<td>No dose adjustment needed</td>
</tr>
</tbody>
</table>

**Consider mesna in patients with pre-existing bladder disorders. Give an oral dose of 40% of the cyclophosphamide dose (rounded upwards to the nearest 400mg) at 0, 2 and 6 hours after the administration of the cyclophosphamide.

Other

Dose reductions or interruptions in therapy are not necessary for those toxicities that are considered unlikely to be serious or life threatening. For example, alopecia, altered taste or nail changes.
Rituximab

Infusion related adverse reactions have been observed in 10% of patients treated with rituximab.

Rituximab administration is associated with the onset of cytokine release syndrome. This condition is characterised by severe dyspnoea, often accompanied by bronchospasm and hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema. It may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, acute renal failure, elevated lactate dehydrogenase (LDH) and can lead to acute respiratory failure and death. This effect on the lungs may be accompanied by events such as pulmonary interstitial infiltration or oedema, visible on a chest x-ray.

Cytokine release syndrome frequently occurs within one or two hours of initiating the first infusion.

Hypersensitivity reactions, including anaphylaxis, have been reported following the intravenous administration of proteins. In contrast to cytokine release syndrome, true hypersensitivity reactions typically occur within minutes of starting the infusion. Medicinal products for the treatment of allergic reactions should be available for immediate use in the event of hypersensitivity developing during the administration of rituximab.

Use of rituximab maybe associated with an increased risk of progressive multifocal leukoencephalopathy (PML). Patients must be monitored at regular intervals for any new or worsening neurological, cognitive or psychiatric symptoms that may be suggestive of PML. If PML is suspected, further dosing must be suspended until PML has been excluded. If PML is confirmed the rituximab must be permanently discontinued.

The presence of a viral upper respiratory tract infection at the time of treatment may increase the risk of rituximab associated hepatotoxicity. Patients should be assessed for any cold or flu-like symptoms prior to treatment.

Vincristine

Reduce the vincristine dose to 1mg if a NCI-CTC grade 2 motor or grade 3 sensory neurological toxicity occurs. For higher toxicity grades or if toxicity increases despite dose reduction stop the vincristine.
Regimen

21 day cycle for 6 – 8 cycles (6 cycles will be set in ARIA)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Days</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td>750mg/m²</td>
<td>1</td>
<td>Intravenous bolus over 10 minutes</td>
</tr>
<tr>
<td>Rituximab</td>
<td>375mg/m²</td>
<td>1</td>
<td>Intravenous infusion in 500ml sodium chloride 0.9%</td>
</tr>
<tr>
<td>Vincristine</td>
<td>1.4mg/m² (max 2mg)</td>
<td>1</td>
<td>Intravenous bolus in 50ml sodium chloride 0.9% over 10 minutes</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>100mg</td>
<td>1, 2, 3, 4, 5</td>
<td>Oral</td>
</tr>
</tbody>
</table>

Consider initial dose reduction in patients over 70 years of age. Doses may be escalated up to full dose on subsequent cycles according to tolerability.

Dose Information

- Cyclophosphamide will be dose banded according to the CSCCN agreed bands
- Rituximab will be dose rounded to the nearest 100mg (up if halfway)
- Vincristine dose will be rounded to the nearest 0.1mg (up if halfway)
- The maximum dose of vincristine is 2mg

Administration Information

Extravasation

- Cyclophosphamide – neutral
- Rituximab - neutral
- Vincristine - vesicant

Other

- Prednisolone should be taken in the morning with or after food. Administration of prednisolone begins on the morning of chemotherapy.
- The rate of administration of rituximab varies. Please refer to the rituximab administration guidelines
Additional Therapy

- **Antiemetics**
  
  15-30 minutes prior to chemotherapy
  
  - ondansetron 8mg oral or intravenous

  As take home medication
  
  - metoclopramide 10mg three times a day when required oral
  - ondansetron 8mg twice a day for 3 days oral

- **Rituximab pre-medication**
  
  30 minutes prior to rituximab
  
  - chlorphenamine 10mg intravenous
  - paracetamol 1000mg oral

  On the morning of treatment
  
  - prednisolone 100mg oral to be self administered by the patient on the morning of treatment and for four days after rituximab treatment (this is part of the chemotherapy schedule as well as rituximab pre-medication)

- **Rituximab infusion reactions**
  
  - hydrocortisone 100mg intravenous when required for rituximab infusion related reactions
  - salbutamol 2.5mg nebule when required for rituximab related bronchospasm
  - consider pethidine 25-50mg intravenous for rituximab related rigors that fail to respond to steroids.

- **Allopurinol 300mg once a day oral for the first cycle only**

- **Consider anti-infective prophylaxis in high risk patients, including:**
  
  - aciclovir 400mg twice a day oral
  - co-trimoxazole 960mg once a day on Monday, Wednesday and Friday only oral

- **Mouthwashes according to local or national policy on the treatment of mucositis**

- **Gastric protection with a proton pump inhibitor or a H2 antagonist may be considered in patients considered at high risk of GI ulceration or bleed.**
Additional Information

- The National Patient Safety Agency report NPSA/2008/RRR04 must be followed in relation to intravenous administration of vinca alkaloids.

Coding (OPCS 4.6)

- Procurement – X71.3
- Delivery – X72.2

References
2. NICE guidance – TA137 Lymphoma (follicular non-Hodgkin’s) rituximab. February 2008
REGIMEN SUMMARY
RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine

Cycle 1

1. Warning – Check patient has taken the prednisolone dose*

2. Chlorphenamine 10mg intravenous

3. Paracetamol 1000mg oral

4. Rituximab 375mg/m² intravenous infusion in 500ml sodium chloride 0.9% as per the rituximab administration guidelines

5. Ondansetron 8mg oral or intravenous injection

6. Vincristine 1.4mg/m² (max 2mg) intravenous bolus in 50ml sodium chloride 0.9% over 10 minutes

7. Cyclophosphamide 750mg/m² intravenous bolus over 10 minutes

8. Hydrocortisone 100mg intravenous once only when required for the relief of rituximab infusion related reactions

9. Salbutamol 2.5mg nebulé once only when required for the relief of rituximab related bronchospasm

Take Home Medicines

10. Prednisolone 100mg once a day on the morning of the next treatment**

11. Prednisolone 100mg once a day for 4 days oral (starting on day 2)**

12. Metoclopramide 10mg three times a day when required oral

13. Ondansetron 8mg twice a day for 3 days oral starting on the evening of day one of treatment

14. Allopurinol 300mg once a day oral for 21 days
Cycles 2, 3, 4 and 5

1. Warning – Check patient has taken the prednisolone dose*
2. Chlorphenamine 10mg intravenous
3. Paracetamol 1000mg oral
4. Rituximab 375mg/m$^2$ intravenous infusion in 500ml sodium chloride 0.9% as per the rituximab administration guidelines
5. Ondansetron 8mg oral or intravenous injection
6. Vincristine 1.4mg/m$^2$ (max 2mg) intravenous bolus in 50ml sodium chloride 0.9% over 10 minutes
7. Cyclophosphamide 750mg/m$^2$ intravenous bolus over 10 minutes
8. Hydrocortisone 100mg intravenous once only when required for the relief of rituximab infusion related reactions
9. Salbutamol 2.5mg nebulé once only when required for the relief of rituximab related bronchospasm

Take Home Medicines

10. Prednisolone 100mg once a day on the morning of the next treatment**
11. Prednisolone 100mg once a day for 4 days oral (starting on day 2)**
12. Metoclopramide 10mg three times a day when required oral
13. Ondansetron 8mg twice a day for 3 days oral starting on the evening of day one of treatment

Cycles 6

1. Warning – Check patient has taken the prednisolone dose*
2. Chlorphenamine 10mg intravenous
3. Paracetamol 1000mg oral
4. Rituximab 375mg/m$^2$ intravenous infusion in 500ml sodium chloride 0.9% as per the rituximab administration guidelines
5. Ondansetron 8mg oral or intravenous injection
6. Vincristine 1.4mg/m$^2$ (max 2mg) intravenous bolus in 50ml sodium chloride 0.9% over 10 minutes
7. Cyclophosphamide 750mg/m$^2$ intravenous bolus over 10 minutes
8. Hydrocortisone 100mg intravenous once only when required for the relief of rituximab infusion related reactions

9. Salbutamol 2.5mg nebulize once only when required for the relief of rituximab related bronchospasm

**Take Home Medicines**

10. Prednisolone 100mg once a day for 4 days oral (starting on day 2)

11. Metoclopramide 10mg three times a day when required oral

12. Ondansetron 8mg twice a day for 3 days oral starting on the evening of day one of treatment

Administration information

* Please check the patient has taken prednisolone 100mg oral on the morning of rituximab administration. On occasions where individuals attend for treatment and have forgotten to take the prednisolone dose please administer prednisolone 100mg oral 30 minutes prior to rituximab administration.

**The prednisolone may be dispensed as a single supply in one container or as two containers depending on local preference**
This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts:

- Hampshire Hospitals NHS Foundation Trust
- NHS Isle of Wight
- Portsmouth Hospitals NHS Trust
- Salisbury Hospitals NHS Foundation Trust
- University Hospital Southampton NHS Foundation Trust
- Western Sussex Hospitals NHS Foundation Trust

All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors which occur as a result of following these guidelines.